Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

338
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
338
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

931
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
931
Muscle Stimulation Frequency01:22

Muscle Stimulation Frequency

2.1K
The contraction strength of muscles is regulated by motor neurons, which modulate the frequency of action potentials dispatched to the motor units based on the body's requirements. This process of varying the muscle stimulation frequency allows muscles to contract with a force that is precisely tailored to the needs of the moment, whether lifting a feather or a heavy box.
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
2.1K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

356
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
356
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

480
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
480

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point of view: Task-specific movement disorders-time for a reappraisal?

Parkinsonism & related disorders·2026
Same author

Estimation of macrophage migration inhibitory factor in gingival crevicular fluid of obese and non-obese patients with periodontitis using ELISA: a case control study.

Quintessence international (Berlin, Germany : 1985)·2026
Same author

RRP12 Variants Are Associated With Autosomal Recessive Brain Calcifications.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Myoclonus, dystonia and parkinsonism due to a de novo novel variant in the NUS1 gene: Furthering the epilepsy-dyskinesia spectrum - Expert commentary.

Parkinsonism & related disorders·2025
Same author

Deep Phenotyping of Musicians' Upper Limb Dystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)·2025
Same author

The Spectrum of Neurologic Phenotypes Associated With NUS1 Pathogenic Variants: A Comprehensive Case Series.

Annals of neurology·2025
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
Same journal

Functional movement disorders: diagnosis, pathophysiology, and treatment.

Current opinion in neurology·2026
Same journal

Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities: Erratum.

Current opinion in neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
10:08

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders

Published on: August 25, 2022

3.0K

Myoclonus: an update.

Betsy Thomas1, Steven J Frucht

  • 1Department of Neurology, NYU Langone Health, New York, New York, USA.

Current Opinion in Neurology
|May 24, 2024
PubMed
Summary
This summary is machine-generated.

Myoclonus, a movement disorder, has new identified causes and genetic links. Research explores specific scenarios like SARS-CoV-2-related myoclonus and promising treatments, including perampanel.

More Related Videos

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 25, 2025

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
10:08

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders

Published on: August 25, 2022

3.0K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K

Area of Science:

  • Neurology
  • Movement Disorders
  • Genetics

Background:

  • Myoclonus is a disabling hyperkinetic movement disorder requiring accurate classification for effective management.
  • While core diagnostic methods remain consistent, emerging causes, triggers, and genetic underpinnings are continually being identified.
  • Treatment for myoclonus presents challenges, yet novel therapeutic options show promise.

Purpose of the Study:

  • To outline the classification and treatment of myoclonus.
  • To discuss recent findings on specific myoclonus presentations and genetic associations.
  • To highlight promising new treatment modalities for myoclonus.

Main Methods:

  • Review of current literature on myoclonus classification and treatment.
  • Discussion of specific clinical scenarios: SARS-CoV-2-associated myoclonus, spinal myoclonus, and auricular myoclonus.
  • Exploration of new genetic findings in myoclonus-dystonia and preliminary data on perampanel efficacy.

Main Results:

  • Identification of myoclonus associated with SARS-CoV-2 infection.
  • Description of spinal myoclonus post-surgery/anesthesia and auricular myoclonus.
  • Report of new genetic findings in myoclonus-dystonia and positive preliminary results for perampanel treatment.

Conclusions:

  • Understanding unique myoclonus scenarios enhances knowledge of causes, genetics, prognosis, and treatment.
  • Further research is crucial for tailoring treatments to specific types of myoclonus.
  • Advances in identifying causes and genetic factors are improving the management of myoclonus.